<DOC>
	<DOCNO>NCT01767688</DOCNO>
	<brief_summary>This study investigate compare pharmacokinetics single 25-mg dose MK-3102 participant moderate hepatic impairment match healthy participant . The primary hypothesis participant moderately impaired hepatic function , area concentration-time curve time zero infinity ( AUC0-∞ ) similar observe healthy match control participant follow single 25 mg oral dose MK-3102 . Specifically , true ratio ( moderately impair hepatic function patients/healthy match control subject ) geometric mean AUC0-∞ great 2 .</brief_summary>
	<brief_title>A Pharmacokinetic Study MK-3102 Participants With Impaired Hepatic Function ( MK-3102-031 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Impaired Hepatic Function Participants : A diagnosis : 1 . Chronic ( &gt; 6 month ) hepatic insufficiency 2 . Stable ( acute episode illness within previous 2 month due deterioration hepatic function ) hepatic insufficiency feature cirrhosis due etiology Score ChildPugh Scale 7 9 ( moderate hepatic insufficiency ) Estimated creatinine clearance ( CLCr ) &gt; 60 mL/min glomerular filtration rate ( eGFR ) ≥ 60 mL/min/1.73 m^2 Both Impaired Hepatic Function Healthy Participants : In general good health Continuous nonsmoker moderate smoker least 3 month prior study start Body Mass Index ≤39 kg/m^2 Females reproductive potential must negative pregnancy test agree use acceptable birth control method ( ) remain sexually inactive throughout study Nonvasectomized male patient must agree use acceptable birth control method ( ) abstain sexual intercourse trial 3 month study Healthy Participants : History presence alcoholism within past 2 year Presence hepatitis B virus ( HBV ) hepatitis virus C ( HVC ) Both Impaired Hepatic Function Healthy Participants : History presence drug abuse within past 2 year History presence human immunodeficiency virus ( HIV ) History presence significant cardiovascular , pulmonary , renal , hematologic , gastrointestinal ( hepatic impairment ) , endocrine , immunologic , dermatologic , neurological disease Use medication substance ( include prescription counter , health supplement , natural herbal supplement ) discontinue least 14 day prior study start throughout study Has special diet within 28 day prior study start Blood donation within 56 day plasma donation within 7 day prior study start Participation another clinical trial within 28 day study start Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
</DOC>